# Imvaria

> Publicly sourced profile assembled by Optimly, in the Optimly AI Brand Index. Last refreshed 2026-10-04.

- **Business Profile:** https://optimly.ai/brand/imvaria
- **Dataset:** https://optimly.ai/brand/imvaria.json
- **Markdown:** https://optimly.ai/brand/imvaria/llms.txt
- **Official website:** https://imvaria.com
- **Slug:** imvaria
- **Categories:** ai-machine-learning, healthcare-it

## Overview

- **Tagline:** Pioneers 'inferetics' by generating novel physiologic signatures from clinical testing and imaging data using AI; offers the first FDA-authorized tools in ILD and IPF (ScreenDx, Fibresolve); led by physician-engineers from Google and Stanford; provides a simple-to-start, no-integration solution.
Source: Brand's website (https://imvaria.com) · 2026-10-04

- **Description:** IMVARIA pioneers AI inference across clinical testing and imaging to generate novel physiologic signatures, creating "inferetics" – a new category of clinical intelligence. They develop FDA-authorized Software-as-Medical-Device (SaMD) tools, initially focused on lung diseases like ILD and IPF, for clinicians, health systems, and biopharma partners.
Source: Brand's website (https://imvaria.com) · 2026-10-04

## Offerings

- **Core capabilities:**
  - ScreenDx (AI for ILD identification)
  - Fibresolve (AI for IPF diagnosis)
  - The AI Lab (cloud-based data analysis platform)
  - Bronchosolve (AI for non-invasive lung cancer diagnosis).
Source: Brand's website (https://imvaria.com) · 2026-10-04

- **Pricing:** Service-based model, where clinicians refer cases to IMVARIA's AI Lab and receive reports with results; no integration or software required from the client.
Source: Brand's website (https://imvaria.com) · 2026-10-04

## Audience

- **Target industry:** Pulmonologists, qualified clinicians in lung disease care, health systems, clinical trialists, and biopharma partners.
Source: Brand's website (https://imvaria.com) · 2026-10-04

Page last updated 2026-10-17.